Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 207,465
  • Shares Outstanding, K 87,909
  • Annual Sales, $ 4,900 K
  • Annual Income, $ -23,370 K
  • 60-Month Beta 2.20
  • Price/Sales 40.70
  • Price/Cash Flow N/A
  • Price/Book 2.88
Trade IMMP with:

Options Overview Details

View History
  • Implied Volatility 115.20% ( -19.02%)
  • Historical Volatility 73.41%
  • IV Percentile 25%
  • IV Rank 11.02%
  • IV High 992.55% on 10/27/22
  • IV Low 6.49% on 01/18/22
  • Put/Call Vol Ratio 0.01
  • Today's Volume 149
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 2,750
  • Open Int (30-Day) 3,744

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.78 +38.55%
on 10/31/22
2.58 -4.41%
on 11/29/22
+0.62 (+33.31%)
since 10/28/22
3-Month
1.47 +67.77%
on 09/29/22
2.58 -4.41%
on 11/29/22
+0.47 (+23.31%)
since 08/29/22
52-Week
1.47 +67.77%
on 09/29/22
3.64 -32.25%
on 01/05/22
-0.93 (-27.46%)
since 11/26/21

Most Recent Stories

More News
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Presents New and Significant Data from the AIPAC Study

Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the...

IMMP : 2.50 (+5.72%)
IMM.AX : 0.365 (+4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the...

See More

Key Turning Points

3rd Resistance Point 2.89
2nd Resistance Point 2.73
1st Resistance Point 2.55
Last Price 2.50
1st Support Level 2.21
2nd Support Level 2.05
3rd Support Level 1.87

See More

52-Week High 3.64
Fibonacci 61.8% 2.81
Fibonacci 50% 2.56
Last Price 2.50
Fibonacci 38.2% 2.30
52-Week Low 1.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar